Efficacy and Safety of a Hyaluronic Acid–Containing Cream in the Treatment of Chronic, Venous, or Mixed-Origin Leg Ulcers

^a P=.009 vs neutral cream
^b P=.010
^c P=.029

ADE: adverse device event; AE: adverse event; SAE; serious adverse event; TEAE: treatment-emergent adverse event

ADE: adverse device event; AE: adverse event; SAE; serious adverse event; TEAE: treatment-emergent adverse event; Tx: treatment
^aAn individual could have more than one event.

Authors and Disclosures

Jacek Mikosinski, MD, PhD¹, Anna Di Landro, MD², Karolina Kasztalska-Kazmierczak, PhD³, Emilie Soriano, MSc, PharmD⁴, Carol Caverzasio, MSc⁵, Daniela Binelli, MStat⁵, Bruno Falissard, MD, PhD⁶ and Olivier Dereure, MD, PhD<sup>7

1</sup>Nzoz Mikomed, ul., Łódź, Poland; ²Centro Studi GISED, Bergamo, Italy; ³CROMSOURCE, Verona, Italy; ⁴IBSA Pharma SAS (previously Laboratoires GENEVRIER), Antibes, France; ⁵IBSA Institut Biochimique S.A., Pambio-Noranco, Lugano, Switzerland; ⁶Director, Centre de Recherche en Epidemiologie et Santé des Populations, Maison de Solenn, 75679 Paris, France; ⁷Department of Dermatology, Hospital Saint-Eloi, Montpellier, France

Correspondence
Carol Caverzasio, MSc, IBSA Institut Biochimique S.A., Via del Piano, 29, 6915 Pambio-Noranco (TI), Switzerland; carol.caverzasio@ibsa.ch

Disclosure
The study was sponsored and funded by IBSA Institut Biochimique S.A. CC and DB are employees of IBSA. ES was an employee of Laboratoires Genevrier at the time the manuscript was conceived and prepared. KK is an employee of CROMSOURCE. Centro Studi GISED received a grant from IBSA, ADL is a member of GISED. JM was the coordinating investigator of the study. BF and OD were members of the data review board of the study, and both received a grant from IBSA Pharma SAS.